Ball-and-stick model of sirolimus, the prototype mTOR inhibitor
|Mechanism of action||mTOR inhibition|
|Biological target|| • FKBP12|
mTOR inhibitors are a class of drugs that inhibit the mammalian target of rapamycin (mTOR), which is a serine/threonine-specific protein kinase that belongs to the family of phosphatidylinositol-3 kinase (PI3K) related kinases (PIKKs). mTOR regulates cellular metabolism, growth, and proliferation by forming and signaling through two protein complexes, mTORC1 and mTORC2. The most established mTOR inhibitors are so-called rapalogs (rapamycin and its analogs), which have shown tumor responses in clinical trials against various tumor types.
- 1 History
- 2 Protein kinases and their inhibitors
- 3 mTOR signaling pathway
- 4 Development of mTOR inhibitors
- 5 Mechanism of action
- 6 Structure activity relationship
- 7 Adverse events
- 8 Biomarkers
- 9 ATP-competitive mTOR kinase inhibitors
- 10 Future
- 11 See also
- 12 References
The discovery of mTOR was made a few decades ago while investigating the mechanism of action of its inhibitor, rapamycin. Rapamycin was first discovered in 1975 in a soil sample from Easter Island of South Pacific, also known as Rapa Nui, from where its name is derived. Rapamycin is a macrolide, produced by the microorganism Streptomyces hygroscopicus and showed antifungal properties. Shortly after its discovery, immunosuppressive properties were detected, which later led to the establishment of rapamycin as an immunosuppressant. In the 1980s, rapamycin was also found to have anticancer activity although the exact mechanism of action remained unknown until many years later.
In the 1990s there was a dramatic change in this field due to studies on the mechanism of action of rapamycin and the identification of the drug target. It was found that rapamycin inhibited cellular proliferation and cell cycle progression. Research on mTOR inhibition has been a growing branch in science and has promising results.
Protein kinases and their inhibitors
In general, protein kinases are classified in two major categories based on their substrate specificity, protein tyrosine kinases and protein serine/threonine kinases. Dual-specificity kinases are subclass of the tyrosine kinases.
mTOR is a kinase within the family of phosphatidylinositol-3 kinase-related kinases (PIKKs), which is a family of serine/threonine protein kinases, with a sequence similarity to the family of lipid kinases, PI3Ks. These kinases have different biological functions, but are all large proteins with common domain structure.
PIKKs have four domains at the protein level, which distinguish them from other protein kinases. From the N-terminus to the C-terminus, these domains are named FRAP-ATM-TRAAP (FAT), the kinase domain (KD), the PIKK-regulatory domain (PRD), and the FAT-C-terminal (FATC). The FAT domain, consisting of four α-helices, is N-terminal to KD, but that part is referred to as the FKBP12-rapamycin-binding (FRB) domain, which binds the FKBP12-rapamycin complex. The FAT domain consists of repeats, referred to as HEAT (Huntingtin, Elongation factor 3, A subunit of protein phosphatase 2A and TOR1). Specific protein activators regulate the PIKK kinases but binding of them to the kinase complex causes a conformational change that increases substrate access to the kinase domain.
Protein kinases have become popular drug targets. They have been targeted for the discovery and design of small molecule inhibitors and biologics as potential therapeutic agents. Small-molecule inhibitors of protein kinases generally prevent either phosphorylation of proteins substrates or autophosphorylation of the kinase itself.
mTOR signaling pathway
It appears that growth factors, amino acids, ATP, and oxygen levels regulate mTOR signaling. Several downstream pathways that regulate cell-cycle progression, translation, initiation, transcriptional stress responses, protein stability, and survival of cells are signaling through mTOR.
The serine/threonine kinase mTOR is a downstream effector of the PI3K/AKT pathway, and forms two distinct multiprotein complexes, mTORC1 and mTORC2. These two complexes have a separate network of protein partners, feedback loops, substrates, and regulators. mTORC1 consists of mTOR and two positive regulatory subunits, raptor and mammalian LST8 (mLST8), and two negative regulators, proline-rich AKT substrate 40 (PRAS40) and DEPTOR. mTORC2 consists of mTOR, mLST8, mSin1, protor, rictor, and DEPTOR.
mTORC1 is sensitive to rapamycin but mTORC2 is considered to be resistant and is generally insensitive to nutrients and energy signals. mTORC2 is activated by growth factors, phosphorylates PKCα, AKT and paxillin, and regulates the activity of the small GTPase, Rac, and Rho related to cell survival, migration and regulation of the actin cytoskeleton.
mTOR signaling pathway in human cancer
Many human tumors occur because of dysregulation of mTOR signaling, and can confer higher susceptibility to inhibitors of mTOR. Deregulations of multiple elements of the mTOR pathway, like PI3K amplification/mutation, PTEN loss of function, AKT overexpression, and S6K1, 4EBP1, and eIF4E overexpression have been related to many types of cancers. Therefore, mTOR is an interesting therapeutic target for treating multiple cancers, both the mTOR inhibitors themselves or in combination with inhibitors of other pathways.
Upstream, PI3K/AKT signalling is deregulated through a variety of mechanisms, including overexpression or activation of growth factor receptors, such as HER-2 (human epidermal growth factor receptor 2) and IGFR (insulin-like growth factor receptor), mutations in PI3K and mutations/amplifications of AKT. Tumor suppressor phosphatase and tensin homologue deleted on chromosome 10 (PTEN) is a negative regulator of PI3K signaling. In many cancers the PTEN expression is decreased and may be downregulated through several mechanisms, including mutations, loss of heterozygosity, methylation, and protein instability.
Downstream, the mTOR effectors S6 kinase 1 (S6K1), eukaryotic initiation factor 4E-binding protein 1 (4EBP1) and eukaryotic initiation factor 4E (eIF4E) are related to cellular transformation. S6K1 is a key regulator of cell growth and also phosphorylates other important targets. Both eIF4E and S6K1 are included in cellular transformation and their overexpression has been linked to poor cancer prognosis.
Development of mTOR inhibitors
Since the discovery of mTOR, much research has been done on the subject, using rapamycin and rapalogs to understand its biological functions. The clinical results from targeting this pathway were not as straight forward as thought at first. Those results have changed the course of clinical research in this field.
Initially, rapamycin was developed as an antifungal drug against Candida albicans, Aspergillus fumigatus and Cryptococcus neoformans. Few years later its immunosuppressive properties were detected. Later studies led to the establishment of rapamycin as a major immunosuppressant against transplant rejection, along with cyclosporine A. By using rapamycin in combination with cyclosporin A, it enhanced the rejection prevention in renal transplantation. Therefore, it was possible to use lower doses of cyclosporine which minimized toxicity of the drug.
In the 1980s rapamycin was evaluated by the Developmental Therapeutic Branch of the National Cancer Institute (NCI). It was discovered that rapamycin had an anticancer activity and was a non-cytotoxic agent with cytostatic activity against several human cancer types. However, due to unfavorable pharmacokinetic properties, the development of mTOR inhibitors for the treatment of cancer was not successful at that time. Since then, rapamycin has also shown to be effective for preventing coronary artery re-stenosis and for the treatment of neurodegenerative diseases.
First generation mTOR inhibitors
The development of rapamycin as an anticancer agent began again in the 1990s with the discovery of temsirolimus (CCI-779). This was a novel soluble rapamycin derivative that had a favorable toxicological profile in animals. More rapamycin derivatives with improved pharmacokinetics and reduced immunosuppressive effects have since then been developed for the treatment of cancer. These rapalogs include temsirolimus (CCI-779), everolimus (RAD001), and ridaforolimus (AP-23573) which are being evaluated in cancer clinical trials. Rapamycin analogs have similar therapeutic effects as rapamycin. However they have improved hydrophilicity and can be used for oral and intravenous administration. In 2012 National Cancer Institute listed more than 200 clinical trials testing the anticancer activity of rapalogs both as monotherapy or as a part of combination therapy for many cancer types.
Rapalogs, which are the first generation mTOR inhibitors, have proven effective in a range of preclinical models. However, the success in clinical trials is limited to only a few rare cancers. Animal and clinical studies show that rapalogs are primarily cytostatic, and therefore effective as disease stabilizers rather than for regression. The response rate in solid tumors where rapalogs have been used as a single-agent therapy have been modest. Due to partial mTOR inhibition as mentioned before, rapalogs are not sufficient for achieving a broad and robust anticancer effect, at least when used as monotherapy.
Another reason for the limited success is that there is a feedback loop between mTORC1 and AKT in certain tumor cells. It seems that mTORC1 inhibition by rapalogs fails to repress a negative feedback loop that results in phosphorylation and activation of AKT. These limitations have led to the development of the second generation of mTOR inhibitors.
Rapamycin and rapalogs
Rapamycin and rapalogs (rapamycin derivatives) are small molecule inhibitors, which have been evaluated as anticancer agents. The rapalogs have more favorable pharmacokinetic profile compared to rapamycin, the parent drug, despite the same binding sites for mTOR and FKBP12.
The bacterial natural product rapamycin or sirolimus, a cytostatic agent, has been used in combination therapy with corticosteroids and cyclosporine in patients who received kidney transplantation to prevent organ rejection both in the US and Europe, due to its unsatisfying pharmacokinetic properties. In 2003, the U.S. Food and Drug Administration approved sirolimus-eluting coronary stents, which are used in patients with narrowing of coronary arteries, or so-called atherosclerosis.
Recently rapamycin has shown effective in the inhibition of growth of several human cancers and murine cell lines. Rapamycin is the main mTOR inhibitor, but deforolimus (AP23573), everolimus (RAD001), and temsirolimus (CCI-779), are the newly developed rapamycin analogs.
Temsirolimus is pro-drug of rapamycin. It is approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), for the treatment of renal cell carcinoma (RCC). Temsirolimus has higher water solubility than rapamycin and is therefore administrated by intravenous injection. It was approved in May 30, 2007, by FDA for the treatment of advanced RCC.
Temsirolimus has also been used in a Phase I clinical trial in conjunction with neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor. This study enrolled patients being treated for HER2-amplified breast cancer, HER2-mutant non-small-cell lung cancer, and other advanced solid tumors. While common toxicities included nausea, stomatitis, and anemia; responses were noted.
Everolimus is the second novel Rapamycin analog. From March 30, 2009 to May 5, 2011 the U.S. FDA approved everolimus for the treatment of advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib, subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis (TS), and progressive neuroendocrine tumors of pancreatic origin (PNET). In July and August 2012, two new indications were approved, for advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane, and pediatric and adult patients with SEGA. In 2009 and 2011, it was also approved throughout the European Union for advanced breast cancer, pancreatic neuroendocrine tumours, advanced renal cell carcinoma, and SEGA in patients with tuberous sclerosis.
Ridaforolimus (AP23573, MK-8669), or deforolimus, is the newest rapamycin analog and it is not a prodrug. Like temsirolimus it can be administrated intravenously, and oral formulation is being estimated for treatment of sarcoma. It was not on market in June 2012, since FDA wanted more human testing on it due to its effectiveness and safety.
Second generation mTOR inhibitors
The second generation of mTOR inhibitors is known as ATP-competitive mTOR kinase inhibitors. mTORC1/mTORC2 dual inhibitors are designed to compete with ATP in the catalytic site of mTOR. They inhibit all of the kinase-dependent functions of mTORC1 and mTORC2 and therefore, block the feedback activation of PI3K/AKT signaling, unlike rapalogs that only target mTORC1. These types of inhibitors have been developed and several of them are being tested in clinical trials. Like rapalogs, they decrease protein translation, attenuate cell cycle progression, and inhibit angiogenesis in many cancer cell lines and also in human cancer. In fact they have been proven to be more potent than rapalogs.
Theoretically, the most important advantages of these mTOR inhibitors is the considerable decrease of AKT phosphorylation on mTORC2 blockade and in addition to a better inhibition on mTORC1. However, some drawbacks exist. Even though these compounds have been effective in rapamycin-insensitive cell lines, they have only shown limited success in KRAS driven tumors. This suggests that combinational therapy may be necessary for the treatment of these cancers. Another drawback is also their potential toxicity. These facts have raised concerns about the long term efficacy of these types of inhibitors.
The close interaction of mTOR with the PI3K pathway has also led to the development of mTOR/PI3K dual inhibitors. Compared with drugs that inhibit either mTORC1 or PI3K, these drugs have the benefit of inhibiting mTORC1, mTORC2, and all the catalytic isoforms of PI3K. Targeting both kinases at the same time reduces the upregulation of PI3K, which is typically produced with an inhibition on mTORC1. The inhibition of the PI3K/mTOR pathway has been shown to potently block proliferation by inducing G1 arrest in different tumor cell lines. Strong induction of apoptosis and autophagy has also been seen. Despite good promising results, there are preclinical evidence that some types of cancers may be insensitive to this dual inhibition. The dual PI3K/mTOR inhibitors are also likely to have increased toxicity.
Mechanism of action
The studies of rapamycin as immunosuppressive agent enabled us to understand its mechanism of action. It inhibits T-cell proliferation and proliferative responses induced by several cytokines, including interleukin 1 (IL-1), IL-2, IL-3, IL-4, IL-6, IGF, PDGF, and colony-stimulating factors (CSFs). Rapamycin inhibitors and rapalogs can target tumor growth both directly and indirectly. Direct impact of them on cancer cells depend on the concentration of the drug and certain cellular characteristics. The indirect way, is based on interaction with processes required for tumor angiogenesis.
Effects in cancer cells
Rapamycin and rapalogs crosslink the immunophilin FK506 binding protein, tacrolimus or FKBP-12, through its methoxy group. The rapamycin-FKBP12 complex interferes with FRB domain of mTOR. Molecular interaction between FKBP12, mTOR, and rapamycin can last for about three days (72 hours). The inhibition of mTOR blocks the binding of the accessory protein raptor (regulatory-associated protein of mTOR) to mTOR, but that is necessary for downstream phosphorylation of S6K1 and 4EBP1.
As a consequence, S6K1 dephosphorylates, which reduces protein synthesis and decreases cell motality and size. Rapamycin induces dephosphorylation of 4EBP1 as well, resulting in an increase in p27 and a decrease in cyclin D1 expression. That leads to late blockage of G1/S cell cycle. Rapamycin has shown to induce cancer cell death by stimulating autophagy or apoptosis, but the molecular mechanism of apoptosis in cancer cells has not yet been fully resolved. One suggestion of the relation between mTOR inhibition and apoptosis might be through the downstream target S6K1, which can phosphorylate BAD, a pro-apoptotic molecule, on Ser136. That reaction breaks the binding of BAD to BCL-XL and BCL2, a mitochondrial death inhibitors, resulting in inactivation of BAD and decreased cell survival. Rapamycin has also shown to induce p53-independent apoptosis in certain types of cancer.
Effects on tumor angiogenesis
Tumor angiogenesis rely on interactions between endothelial vascular growth factors which can all activate the PI3K/AKT/mTOR in endothelial cells, pericytes, or cancer cells. Example of these growth factors are angiopoietin 1 (ANG1), ANG 2, basic fibroblast growth factor (bFGF), ephrin-B2, vascular enothelial growth factor (VEGF), and members of the tumor growth factor-β (TGFβ) superfamily. One of the major stimuli of angiogenesis is hypoxia, resulting in activation of hypoxia-inducible transcription factors (HIFs) and expression of ANG2, bFGF, PDGF, VEGF, and VEGFR. Inhibition of HIF1α translation by preventing PDGF/PDGFR and VEGF/VEGFR can result from mTOR inhibition. A G0-G1 cell-cycle blockage can be the consequence of inactivation of mTOR in hypoxia-activated pericytes and endothelial cells.
Structure activity relationship
The pipecolate region of rapamycin structure seems necessary for rapamycin-binding to FKBP12. This step is required for further binding of rapamycin to the mTOR kinase, which is the key enzyme in many biological actions of rapamycin.
The high affinity of rapamycin binding to FKBP12 is explained by number of hydrogen bonds through two different hydrophobic binding pockets, and this has been revealed by X-ray crystal structure of the compound bound to the protein. The structural characteristics common to temsirolimus and sirolimus; the pipecolic acid, tricarbonyl region from C13-C15, and lactone functionalities play the key role in binding groups with the FKBP12.
The most important hydrogen bonds are the lactone carbonyl oxygen at C-21 to the backbone NH of Ile56, amide carbonyl at C-15 to the phenolic group on the sidechain of Tyr82, and the hydroxyl proton at the hemiketal carbon, C-13, to the sidechain of Asp37.
Structural changes to the rapamycin structure can affect binding to mTOR. This could include both direct and indirect binding as a part of binding to FKBP12. Interaction of the FKBP12-rapamycin complex with mTOR corresponds with conformational flexibility of the effector domain of rapamycin. This domain consists of molecular regions that make hydrophobic interactions with the FKB domain and triene region from C-1-C-6, methoxy group at C-7, and methyl groups at C-33, C-27 and C-25. All changes of the macrolide ring can have unpredictible effects on binding and therefore, make determination of SAR for rapalogs problematic.
Rapamycin contains no functional groups that ionize in the pH range 1-10 and therefore, are rather insoluble in water. Despite its effectiveness in preclinic cancer models, its poor solubility in water, stability, and the long half-life elimination made its parenteral use difficult, but the development of soluble rapamycin analogs vanquished various barriers.
Nonetheless, the rapamycin analogs that have been approved for human use are modified at C-43 hydroxyl group and show improvement in pharmacokinetic parameters as well as drug properties, for example solubility.
Rapamycin and temsirolimus have similar chemical structures and bind to FKBP12, though their mechanism of action differs.
Temsirolimus is a dihydroxymethyl propionic acid ester of rapamycin, and its first derivative. Therefore, it is more water-soluble, and due to its watersolubility it can be given by intravenous formulation.
Deforolimus (Ridaforolimus ) has C43 secondary alcohol moiety of the cyclohexyl group of Rapamycin that was substituted with phosphonate and phosphinate groups, preventing the high-affinity binding to mTOR and FKBP. Computational modelling studies helped the synthesise of the compound.
Treatment with mTOR inhibitors can be complicated by adverse events. The most frequently occurring adverse events are stomatitis, rash, anemia, fatigue, hyperglycemia/hypertriglyceridemia, decreased appetite, nausea, and diarrhea. Additionally, interstitial lung disease is an adverse event of particular importance. mTORi-induced ILD often is asymptomatic (with ground glass abnormalities on chest CT) or mild symptomatic (with a non-productive cough), but can be very severe as well. Even fatalities have been described. Careful diagnosis and treatment therefore is essential. Recently, a new diagnostic and therapeutic management approach has been proposed.
Identification of predictive biomarkers of efficacy for tumor types that are sensitive to mTOR inhibitors remains a major issue. Possible predictive biomarkers for tumor response to mTOR inhibitors, as have been described in glioblastoma, breast and prostate cancer cells, may be the differential expression of mTOR pathway proteins, PTEN, AKT, and S6. Thus, this data is based on preclinical assays, based on in vitro cultured tumor cell lines, which suggest that the effects of mTOR inhibitors may be more pronounced in cancers displaying loss of PTEN functions or PIK3CA mutations. However, the use of PTEN, PIK3CA mutations, and AKT–phospho status for predicting rapalog sensitivity has not been fully validated in clinic. To date, attempts to identify biomarkers of rapalog response have been unsuccessful.
Clinical and translational data suggest that sensitive tumor types, with adequate parameters and functional apoptosis pathways, might not need high doses of mTOR inhibitors to trigger apoptosis. In most cases, cancer cells might only be partially sensitive to mTOR inhibitors due to redundant signal transduction or lack of functional apoptosis signaling pathways. In situations like this, high doses of mTOR inhibitors might be required. In recent study of patients with Renal cell carcinoma, resistance to Temsirolimus was associated with low levels of p-AKT and p-S6K1, that play the key role in mTOR activation. These data strongly suggests number of tumors with an activated PI3K/AKT/mTOR signaling pathway that does not respond to mTOR inhibitors. For future studies it is recommended to exclude patients with low or negative p-AKT levels from trials with mTOR inhibitors.
Current data is insufficient to predict sensitivity of tumors to rapamycin. However, the existing data allows us to characterize tumors that might not respond to rapalogs.
ATP-competitive mTOR kinase inhibitors
These second generation mTOR inhibitors bind to ATP-binding site in mTOR kinase domain required for the functions of both mTORC1 and mTORC2, and result in downregulation of mTOR signaling pathway. Due to PI3K and mTORC2 ability to regulate AKT phosphorylation, these two compounds play a key role in minimizing the feedback activation of AKT.
mTOR/PI3K dual inhibitors
Several, so-called mTOR/PI3K dual inhibitors (TPdIs), have been developed and are in early-stage preclinical trials and show promising results. Their development has been benefited from previous studies with PI3K-selective inhibitors. The activity of these small molecules from rapalog activity differs in the way by blocking both mTORC1-dependent phospholylation of S6K1 and mTORC2-dependent phosphorylation of AKT Ser473 residue.
Dual mTOR/PI3K inhibitors include dactolisib, BGT226, SF1126, PKI-587 and many more. For example, Novartis has developed the compound NVPBE235 that was reported to inhibit tumor growth in various preclinical models. It enhances antitumor activity of some other drugs such as vincristine. Dactolisib seems to inhibit effectively both wild-type and mutant form of PI3KCA, which suggests its use towards wide types of tumors. Studies have shown superior antiproliferative activity to rapalogs and in vivo models have confirmed these potent antineoplastic effects of dual mTOR/PI3K inhibitors. These inhibitors target isoforms of PI3K (p110α, β and γ) along with ATP-binding sites of mTORC1 and mTORC2 by blocking PI3K/AKT signaling, even in cancer types with mutations in this pathway.
mTORC1/mTORC2 dual inhibitors (TORCdIs)
New mTOR-specific inhibitors came forth from screening and drug discovery efforts. These compounds block activity of both mTOR complexes and are called mTORC1/mTORC2 dual inhibitors. Compounds with this characteristics such as sapanisertib (codenamed INK128), AZD8055, and AZD2014 have entered clinical trials. A series of these mTOR kinase inhibitors have been studied. Their structure is derived from morpholino pyrazolopyrimidine scaffold. Improvements of this type of inhibitors have been made by exchanging the morpholines with bridged morpholines in pyrazolopyrimidine inhibitors and results showed increased selectivity to mTOR by 26000 fold.
Limitations of new generation mTOR inhibitors
Although the new generation of mTOR inhibitors hold great promise for anticancer therapy and are rapidly moving into clinical trials, there are many important issues that determine their success in the clinic. First of all predictable biomarkers for benefit of these inhibitors are not available. It appears that genetic determinants predispose cancer cells to be sensitive or resistant to these compounds. Tumors that depend on PI3K/mTOR pathway should respond to these agents but it is unclear if compounds are effective in cancers with distinct genetic lesions.
Inhibition of mTOR is a promising strategy for treatment of number of cancers. Limited clinical activity of selective mTORC1 agents have made them unlikely to have impact in cancer treatment. The development of competitive ATP-catalytic inhibitors have the ability to block both mTORC1 and mTORC2.
The limitations of currently available rapalogs have led to new approaches to mTOR targeting. Studies suggest that mTOR inhibitors may have anticancer activity in many cancer types, such as RCC, neuroendocrine tumors, breast cancer, hepatocellular carcinoma, sarcoma, and large B-cell lymphoma. One major limitation for the development of mTOR inhibition therapy is that biomarkers are not presently available to predict which patient will respond to them. A better understanding of the molecular mechanisms that are involved in the response of cancer cells to mTOR inhibitors are still required so this can be possible.
A way to overcome the resistance and improve efficacy of mTOR targeting agents may be with stratification of patients and selection of drug combination therapies. This may lead to a more effective and personalized cancer therapy. Although further research is needed, mTOR targeting still remains an attractive and promising therapeutic option for the treatment of cancer.
- Pópulo, Helena; Lopes, José Manuel; Soares, Paula (2012). "The mTOR Signalling Pathway in Human Cancer". International Journal of Molecular Sciences. 13 (12): 1886–918. doi:10.3390/ijms13021886. PMC 3291999. PMID 22408430.
- Strimpakos, Alex S.; Karapanagiotou, Eleni M.; Saif, M. Wasif; Syrigos, Kostas N. (2009). "The role of mTOR in the management of solid tumors: An overview". Cancer Treatment Reviews. 35 (2): 148–59. doi:10.1016/j.ctrv.2008.09.006. PMID 19013721.
- Yuan, Ruirong; Kay, Andrea; Berg, William J; Lebwohl, David (2009). "Targeting tumorigenesis: Development and use of mTOR inhibitors in cancer therapy". Journal of Hematology & Oncology. 2: 45. doi:10.1186/1756-8722-2-45. PMC 2775749. PMID 19860903.
- Tsang, Chi Kwan; Qi, Haiyan; Liu, Leroy F.; Zheng, X.F. Steven (2007). "Targeting mammalian target of rapamycin (mTOR) for health and diseases". Drug Discovery Today. 12 (3–4): 112–24. doi:10.1016/j.drudis.2006.12.008. PMID 17275731.
- Faivre, Sandrine; Kroemer, Guido; Raymond, Eric (2006). "Current development of mTOR inhibitors as anticancer agents". Nature Reviews Drug Discovery. 5 (8): 671–88. doi:10.1038/nrd2062. PMID 16883305.
- Vignot, S.; Faivre, S; Aguirre, D; Raymond, E (2005). "MTOR-targeted therapy of cancer with rapamycin derivatives". Annals of Oncology. 16 (4): 525–37. doi:10.1093/annonc/mdi113. PMID 15728109.
- Zaytseva, Yekaterina Y.; Valentino, Joseph D.; Gulhati, Pat; Evers, B. (2012). "MTOR inhibitors in cancer therapy". Cancer Letters. 319 (1): 1–7. doi:10.1016/j.canlet.2012.01.005. PMID 22261336.
- Lempiäinen, Harri; Halazonetis, Thanos D (2009). "Emerging common themes in regulation of PIKKs and PI3Ks". The EMBO Journal. 28 (20): 3067–73. doi:10.1038/emboj.2009.281. PMC 2752028. PMID 19779456.
- Lovejoy, Courtney A.; Cortez, David (2009). "Common mechanisms of PIKK regulation". DNA Repair. 8 (9): 1004–8. doi:10.1016/j.dnarep.2009.04.006. PMC 2725225. PMID 19464237.
- McConnell, J. L.; Wadzinski, B. E. (2009). "Targeting Protein Serine/Threonine Phosphatases for Drug Development". Molecular Pharmacology. 75 (6): 1249–61. doi:10.1124/mol.108.053140. PMC 2684880. PMID 19299564.
- Grant, S. K. (2008). "Therapeutic Protein Kinase Inhibitors". Cellular and Molecular Life Sciences. 66 (7): 1163–77. doi:10.1007/s00018-008-8539-7. PMID 19011754.
- https://www.ncbi.nlm.nih.gov/books/NBK9962/[full citation needed]
- Ljungman, Mats (2007). "The transcription stress response". Cell Cycle. 6 (18): 2252–7. doi:10.4161/cc.6.18.4751. PMID 17700065.
- Lipton JO, Sahin M (October 2014). "The neurology of mTOR". Neuron. 84 (2): 275–291. doi:10.1016/j.neuron.2014.09.034. PMC 4223653. PMID 25374355.
Figure 1: Domain structure of the mTOR kinase and components of mTORC1 and mTORC2
Figure 2: The mTOR Signaling Pathway
- Vilar, E.; Perez-Garcia, J.; Tabernero, J. (2011). "Pushing the Envelope in the mTOR Pathway: The Second Generation of Inhibitors". Molecular Cancer Therapeutics. 10 (3): 395–403. doi:10.1158/1535-7163.MCT-10-0905. PMC 3413411. PMID 21216931.
- Meric-Bernstam, F.; Gonzalez-Angulo, A. M. (2009). "Targeting the mTOR Signaling Network for Cancer Therapy". Journal of Clinical Oncology. 27 (13): 2278–87. doi:10.1200/Jco.2008.20.0766. PMC 2738634. PMID 19332717.
- Huang, S; Houghton, PJ (2003). "Targeting mTOR signaling for cancer therapy". Current Opinion in Pharmacology. 3 (4): 371–7. doi:10.1016/S1471-4892(03)00071-7. PMID 12901945.
- Ballou, Lisa M.; Lin, Richard Z. (2008). "Rapamycin and mTOR kinase inhibitors". Journal of Chemical Biology. 1 (1–4): 27–36. doi:10.1007/s12154-008-0003-5. PMC 2698317. PMID 19568796.
- Brachmann, Saskia; Fritsch, Christine; Maira, Saveur-Michel; García-Echeverría, Carlos (2009). "PI3K and mTOR inhibitors—a new generation of targeted anticancer agents". Current Opinion in Cell Biology. 21 (2): 194–8. doi:10.1016/j.ceb.2008.12.011. PMID 19201591.
- Zhang, Yan-Jie; Duan, Yanwen; Zheng, X.F. Steven (2011). "Targeting the mTOR kinase domain: The second generation of mTOR inhibitors". Drug Discovery Today. 16 (7–8): 325–31. doi:10.1016/j.drudis.2011.02.008. PMC 3073023. PMID 21333749.
- Wander, Seth A.; Hennessy, Bryan T.; Slingerland, Joyce M. (2011). "Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy". Journal of Clinical Investigation. 121 (4): 1231–41. doi:10.1172/JCI44145. PMC 3069769. PMID 21490404.
- Tanneeru, Karunakar; Guruprasad, Lalitha (2011). "Ligand-based 3-D pharmacophore generation and molecular docking of mTOR kinase inhibitors". Journal of Molecular Modeling. 18 (4): 1611–24. doi:10.1007/s00894-011-1184-3. PMID 21805127.
- Sutherlin, Daniel P.; Bao, Linda; Berry, Megan; Castanedo, Georgette; Chuckowree, Irina; Dotson, Jenna; Folks, Adrian; Friedman, Lori; Goldsmith, Richard; Gunzner, Janet; Heffron, Timothy; Lesnick, John; Lewis, Cristina; Mathieu, Simon; Murray, Jeremy; Nonomiya, Jim; Pang, Jodie; Pegg, Niel; Prior, Wei Wei; Rouge, Lionel; Salphati, Laurent; Sampath, Deepak; Tian, Qingping; Tsui, Vickie; Wan, Nan Chi; Wang, Shumei; Wei, Binqing; Wiesmann, Christian; Wu, Ping; Zhu, Bing-Yan (2011). "Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer". Journal of Medicinal Chemistry. 54 (21): 7579–87. doi:10.1021/jm2009327. PMID 21981714.
- Simamora, Pahala; Alvarez, Joan M; Yalkowsky, Samuel H (2001). "Solubilization of rapamycin". International Journal of Pharmaceutics. 213 (1–2): 25–9. doi:10.1016/s0378-5173(00)00617-7. PMID 11165091.
- "Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations". Food and Drug Administration. Retrieved 25 September 2012.
- "Rapamune". European Medicines Agency. Retrieved 25 September 2012.
- "CYPHER Sirolimus-eluting Coronary Stent - P020026". Food and Drug Administration. Retrieved 25 September 2012.
- "Torisel". European Medicines Agency. Retrieved 25 September 2012.
- Gandhi L, et al. "MA04.02 Neratinib ± Temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study". Journal of Thoracic Oncology. 12 (1): S358–9. doi:10.1016/j.jtho.2016.11.398.
- "FDA approval for Everolimus". National Cancer Institute. Retrieved 20 September 2012.
- "Afinitor". European Medicines Agency. Retrieved 25 September 2012.
- "Votubia". European Medicines Agency. Retrieved 25 September 2012.
- "FDA Wants More Ridaforolimus Testing". Drug Discovery and Development. Retrieved 20 September 2012.
- Garcia‑Echeverria, Carlos (2011). "Blocking the mTOR pathway: A drug discovery perspective". Biochemical Society Transactions. 39 (2): 451–5. doi:10.1042/BST0390451. PMID 21428918.
- Ritacco, F. V.; Graziani, E. I.; Summers, M. Y.; Zabriskie, T. M.; Yu, K.; Bernan, V. S.; Carter, G. T.; Greenstein, M. (2005). "Production of Novel Rapamycin Analogs by Precursor-Directed Biosynthesis". Applied and Environmental Microbiology. 71 (4): 1971–6. doi:10.1128/AEM.71.4.1971-1976.2005. PMC 1082568. PMID 15812028.
- Abraham, Robert T.; Gibbons, James J.; Graziani, Edmund I. (2010). "Chemistry and Pharmacology of Rapamycin and Its Derivatives". In Hall, Michael N.; Tamanoi, Fuyuhiko. Structure, Function and Regulation of TOR complexes from Yeasts to Mammals. The Enzymes. 27. pp. 329–66. doi:10.1016/S1874-6047(10)27017-8. ISBN 978-0-12-381539-2.
- Barrish, Joel C.; Carter, Percy; Cheng, Peter; et al., eds. (2010). Accounts in Drug Discovery: Case Studies in Medicinal Chemistry. Cambridge: Royal Society of Chemistry. ISBN 978-1-84973-126-3.[page needed]
- Willemsen AE et al. mTOR inhibitor-induced interstitial lung disease in cancer patients: comprehensive review and a practical management algorithm. International Journal of Cancer 2015
- Delbaldo, Catherine; Albert, Sébastien; Dreyer, Chantal; Sablin, Marie-Paule; Serova, Maria; Raymond, Eric; Faivre, Sandrine (2011). "Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors". Targeted Oncology. 6 (2): 119–24. doi:10.1007/s11523-011-0177-6. PMID 21533544.
- Nowak, Pawel; Cole, Derek C.; Brooijmans, Natasja; Bursavich, Matthew G.; Curran, Kevin J.; Ellingboe, John W.; Gibbons, James J.; Hollander, Irwin; Hu, Yongbo; Kaplan, Joshua; Malwitz, David J.; Toral-Barza, Lourdes; Verheijen, Jeroen C.; Zask, Arie; Zhang, Wei-Guo; Yu, Ker (2009). "Discovery of Potent and Selective Inhibitors of the Mammalian Target of Rapamycin (mTOR) Kinase". Journal of Medicinal Chemistry. 52 (22): 7081–9. doi:10.1021/jm9012642. PMID 19848404.
- Altman, Jessica K.; Sassano, Antonella; Platanias, Leonidas C. (2011-06-14). "Targeting mTOR for the treatment of AML. New agents and new directions". Oncotarget. 2 (6): 510–517. doi:10.18632/oncotarget.290. PMC 3248202. PMID 21680954.